A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-64232025 in Healthy Participants
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2019
At a glance
- Drugs JNJ-64232025 (Primary) ; JNJ-64232025 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 22 Jan 2019 Planned End Date changed from 6 Mar 2019 to 6 Feb 2019.
- 22 Jan 2019 Planned primary completion date changed from 6 Mar 2019 to 6 Feb 2019.
- 22 Jan 2019 Status changed from recruiting to active, no longer recruiting.